Skip to main content

Selected Publications

Representative fundamental discoveries and translational trial reports:

Nature Communications 2026 Landmark Clinical Phase II Trial

Quizartinib and omacetaxine mepesuccinate combination therapy in FLT3-ITD AML: a phase II trial

Zheng LC, Wong KKW, Lam SSY, Leung GMK, Li C, Tong KW, Lam W, Zeng XY, Chan KC, Chan NN, Ng KL, Dang CC, Kwok TH, Tsui SP, Sharma R, Wong JWH, Leung SY, Leung AYH, Man CH#

# Corresponding / Senior Author
DOI ↗
Abstract · PMID 41942459

Overcoming acquired resistance to FLT3 inhibitors remains an unmet clinical challenge in acute myeloid leukemia (AML). Here, we report a prospective Phase II trial combining quizartinib with omacetaxine mepesuccinate in FLT3-ITD-positive AML. The regimen demonstrated high overall response rates and prolonged remissions by simultaneously targeting kinase signaling and protein translation machinery.

Blood 2023 Landmark Featured Plenary Paper

Inhibition of PLK4 remodels histone methylation and activates immune response via cGAS-STING pathway in TP53 mutated AML

Man CH*#, Lam W*, Dang CC*, Zeng X, Zheng L, Chan NM, Ng KL, Chan KC, Kwok TH, Ng TC, Leung WY, Huen SY, Wong CL, So CC, Dou Z, Goyama S, Bray MR, Mak TW, Leung AY

* Co-first author; # Corresponding author
DOI ↗
Abstract · PMID 37738460

TP53-mutated AML carries an exceptionally poor prognosis with resistance to conventional therapies. We demonstrated that PLK4 is aberrantly overexpressed in TP53-mutated AML and orchestrates repressive histone methylation. Inhibiting PLK4 disrupts this repressive epigenetic barrier, inducing cytosolic DNA and activating the cGAS-STING innate immune response to selectively eliminate leukemic cells.

Adv Exp Med Biol 2023 Book Chapter / Review

Metabolism in Hematopoiesis and Its malignancy

Zeng X, Wang YP, Man CH#

# Corresponding author
DOI ↗
Abstract · PMID 38228958

A comprehensive review outlining how metabolic checkpoints govern normal hematopoietic stem cell self-renewal and lineage commitment, and discussing metabolic vulnerabilities that arise during leukemogenesis.

Leukemia 2022 Landmark Featured Article

Regulation of proton partitioning in kinase-activating acute myeloid leukemia and its therapeutic implication

Man CH*#, Zeng X*, Lam W*, Ng TC, Kwok TH, Dang KC, Leung TW, Ng NK, Lam SS, Cher CC, Leung AY

* Co-first author; # Corresponding author
DOI ↗
Abstract · PMID 35624145

We characterized how kinase-activating oncogenes reprogram proton flux to sustain an alkaline intracellular pH that fuels leukemic cell survival. Genetic or pharmacological disruption of proton export triggered lethal cellular acidification and oxidative stress selectively in leukemic blasts.

Blood 2022 Landmark Cover & Spotlight Paper (Harvard MGH Work)

Proton export alkalinizes intracellular pH and reprograms carbon metabolism to drive hematopoietic progenitor growth

Man CH*, Mercier FE, Liu N, Dong W, Stephanopoulos G, Jiang L, Jung Y, Lin CP, Leung AY, Scadden DT

* First Author (Conducted with David T. Scadden at Harvard / MGH)
DOI ↗
Abstract · PMID 34610101

Stem and progenitor cells rely on coordinated metabolic adaptations during hematopoietic specification. We uncovered that proton export elevates intracellular pH, serving as an essential metabolic rheostat that redirects carbon fluxes into biosynthetic pathways to drive progenitor cell expansion.

Blood 2015 Research Article

Suppression of SOX7 by DNA methylation and its tumor suppressive role in acute myeloid leukemia

Man CH*, Wan HX*, Fung TK*, Chow HC, Fan AC, Wan TS, Tanaka T, So CW, Kwong YL, Leung AY

* First Author
DOI ↗
Abstract · PMID 25940713

Demonstrated that SOX7 is silenced by aberrant promoter hypermethylation in primary AML. Restoring SOX7 expression repressed Wnt/beta-catenin signaling and curtailed leukemic growth in vivo, establishing its tumor-suppressive function.

Haematologica 2015 Clinical Article

Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-Like Tyrosine Kinase-3 internal tandem duplication positive acute myeloid leukemia

Gill H*, Man CH*, Ip AH, Choi WW, Chow HC, Kwong YL, Leung AY

* Co-first author
DOI ↗
Abstract · PMID 25820334

Demonstrated the efficacy of azacitidine maintenance post-remission in preventing relapse among FLT3-ITD-positive AML patients treated with sorafenib.

Blood 2014 Landmark Featured Article

A novel tescalcin-sodium/hydrogen exchange axis underlying sorafenib resistance in FLT3-ITD AML

Man CH*, Lam SS, Sun MK, Chow HC, Gill H, Kwong YL, Leung AY

* First Author
DOI ↗
Abstract · PMID 24608976

Discovered that the Tescalcin-NHE1 axis is a crucial driver of acquired sorafenib resistance in FLT3-ITD AML, providing an actionable target to sensitize resistant leukemic clones.

Blood 2012 Foundational Article

Sorafenib treatment of FLT3-ITD+ acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent non-responsiveness

Man CH*, Fung TK, Ho C, Han HH, Chow HC, Ma AC, Choi WW, Lok S, Cheung AM, Eaves C, Kwong YL, Leung AY

* First Author
DOI ↗
Abstract · PMID 22368270

Pioneered the clinical and mechanistic characterization of sorafenib therapy in FLT3-ITD+ AML, tracing initial tumor debulking and subsequent resistance evolution.